Benefix Market Report 2026

Benefix Market Overview

• The Benefix market growth in the historic period has been driven by hemophilia b disease burden, plasma safety concerns • Market expansion is supported by increasing prophylaxis uptake, improved recombinant manufacturing • Growth Driver: Rising Hemophilia Prevalence And Improved Diagnostics Are Driving Benefix Market Growth • Asia-Pacific was the largest region and fastest growing region.

What Is Covered Under Benefix Market?

Benefix is a recombinant coagulation factor IX product designed to treat and manage bleeding disorders caused by factor IX deficiency, such as hemophilia B. It is used to prevent and control bleeding episodes, manage perioperative bleeding, and reduce the frequency of spontaneous bleeding in patients with hemophilia B through routine prophylaxis. The main clinical indications in benefix are hemophilia B and surgical prophylaxis. Hemophilia B is a rare genetic bleeding disorder caused by a deficiency of clotting factor IX, leading to prolonged or spontaneous bleeding episodes. The primary users include hospitals, clinics, and homecare settings and it is distributed through direct sales, retail pharmacies, and online pharmacies.

What Is The Benefix Market Growth Forecast?

The growth in the forecast period can be attributed to increasing prophylaxis uptake, improved recombinant manufacturing, pediatric patient adoption, enhanced homecare support, broader treatment access programs. Major trends in the forecast period include shift toward recombinant factor ix therapies, expansion of prophylactic hemophilia management, reduced dependence on plasma derived factors, improved home based bleeding management, rising adoption of routine preventive dosing.

Global Benefix Market Segmentation

1) By Clinical Indication: Hemophilia B, Surgical Prophylaxis 2) By End User: Hospitals, Clinics, Homecare Settings 3) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Pharmacies

What Are The Drivers Of The Benefix Market?

The rising prevalence of hemophilia is expected to propel the growth of the benefix market going forward. Healthcare expenditure refers to the total amount of financial resources spent on healthcare services, products, and infrastructure. The increasing demand for healthcare expenditure is due to the rising prevalence of chronic diseases, which require long-term and costly treatments. Benefix aids in effective hemophilia management by delivering recombinant factor IX therapy, making it suitable for patients with factor IX deficiency. It improves treatment reliability by helping prevent and control bleeding episodes quickly, enhancing patient safety and overall quality of life. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,788 patients living with hereditary haemophilia A (HMA) in 2023-2024, up from 2,681 patients in 2022-2023. Therefore, the rising prevalence of hemophilia is driving the growth of the benefix industry. A rising focus on rare diseases is expected to drive the benefix market going forward. Rare diseases are medical conditions that affect a small percentage of the population, typically fewer than 1 in 2,000 individuals. The increased focus on rare diseases is driven by advances in medical research, improved diagnostic technologies, and greater patient advocacy that has led to more awareness and the development of targeted treatments. Benefix offers an effective treatment for hemophilia B, a rare genetic bleeding disorder, helping to advance the care and management of affected individuals by providing a consistent clotting solution that minimizes the need for frequent infusions and supports improved quality of life. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the USFDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from 6 personalized treatments in 2022. Therefore, a rising focus on rare diseases is driving the benefix industry. The rising healthcare expenditure is expected to boost the growth of the benefix market going forward. Healthcare expenditure refers to the total amount spent on health services and related activities within a certain period, typically measured annually. Rising healthcare expenditure is due to an aging population, chronic diseases, higher service prices, increased demand, technological advancements, rising drug costs, the COVID-19 impact, medical inflation, and income polarization. Rising healthcare expenditure enhances Benefix utilization by improving access to advanced recombinant factor IX therapies, making them more widely available for hemophilia B patients. It strengthens treatment outcomes by enabling investment in high-quality biologics, supporting better bleeding control and overall patient care. For instance, in 2023, according to the Centers for Medicare & Medicaid Services (CMS), a US-based government agency, U.S. health care spending increased by 7.5% to $4.9 trillion, up from $4.5 trillion in 2022. Therefore, the rising healthcare expenditure is driving the growth of the Benefix industry.

Key Players In The Global Benefix Market

Major companies operating in the benefix market are Pfizer Inc.

Regional Insights

Asia-Pacific was the largest region in the benefix market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Benefix Market?

The benefix market consists of sales of products such as single-use vials, alprolix, beneFix+, and xyntha. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Benefix Market Report 2026?

The benefix market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the benefix industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.